These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1669 related articles for article (PubMed ID: 30609922)

  • 1. Probiotics, prebiotics and amelioration of diseases.
    Tsai YL; Lin TL; Chang CJ; Wu TR; Lai WF; Lu CC; Lai HC
    J Biomed Sci; 2019 Jan; 26(1):3. PubMed ID: 30609922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota and inflammatory bowel disease: so far so gut!
    Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.
    Schulberg J; De Cruz P
    Intern Med J; 2016 Mar; 46(3):266-73. PubMed ID: 26968595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of probiotics and prebiotics with the gut microbiota.
    Ballan R; Battistini C; Xavier-Santos D; Saad SMI
    Prog Mol Biol Transl Sci; 2020; 171():265-300. PubMed ID: 32475525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
    Amabebe E; Robert FO; Agbalalah T; Orubu ESF
    Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet.
    Liu X; Cao S; Zhang X
    J Agric Food Chem; 2015 Sep; 63(36):7885-95. PubMed ID: 26306709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Microbiome and Antibiotics in Autoimmune Diseases.
    Vangoitsenhoven R; Cresci GAM
    Nutr Clin Pract; 2020 Jun; 35(3):406-416. PubMed ID: 32319703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Tsigalou C; Dalamaga M
    Curr Obes Rep; 2020 Sep; 9(3):179-192. PubMed ID: 32472285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.
    Li HY; Zhou DD; Gan RY; Huang SY; Zhao CN; Shang A; Xu XY; Li HB
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases.
    Oniszczuk A; Oniszczuk T; Gancarz M; Szymańska J
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33671813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome a promising target for management of respiratory diseases.
    Trivedi R; Barve K
    Biochem J; 2020 Jul; 477(14):2679-2696. PubMed ID: 32726437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics, probiotics and prebiotics in IBD.
    Bernstein CN
    Nestle Nutr Inst Workshop Ser; 2014; 79():83-100. PubMed ID: 25227297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered.
    Qiao YQ; Cai CW; Ran ZH
    J Dig Dis; 2016 Dec; 17(12):800-810. PubMed ID: 27743467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota in common elderly diseases affecting activities of daily living.
    Shimizu Y
    World J Gastroenterol; 2018 Nov; 24(42):4750-4758. PubMed ID: 30479462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the microbiome for human health: from basic science to clinical applications.
    Mohajeri MH; Brummer RJM; Rastall RA; Weersma RK; Harmsen HJM; Faas M; Eggersdorfer M
    Eur J Nutr; 2018 May; 57(Suppl 1):1-14. PubMed ID: 29748817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics.
    Maguire M; Maguire G
    Rev Neurosci; 2019 Jan; 30(2):179-201. PubMed ID: 30173208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.